Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, PR China.
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, PR China.
J Mol Graph Model. 2019 Jan;86:95-105. doi: 10.1016/j.jmgm.2018.10.009. Epub 2018 Oct 10.
The interaction of GluN2B-Containing NMDA Receptor with 18 antagonists were investigated by a combined ligand-based and target-based approach. First, two distinct pharmacophore models were generated for antagonists which cluster in two groups with Catalyst (HipHop module). The pharmacophore of "ifenprodil group" antagonists includes three hydrophobic groups, one H-bond donor and one H-bond acceptor, the pharmacophore of "EVT101 group" antagonists involves one aromatic ring, two hydrophobic groups and one H-bond acceptor. Docking results and pharmacophore model confrontation allow the pharmacodynamic characteristics to be weighted and structural information integrated. Which results in the proposal of two interaction models inside the GluN2B binding cavity for two groups of antagonists. The interaction model of "ifenprodil group" antagonists consists of one hydrophobic group, one H-bond donor, one H-bond acceptor and an aromatic ring, while on the other hand, the interaction model of "EVT101 group" antagonists includes three hydrophobic groups and an aromatic ring.
通过基于配体和基于靶点的联合方法研究了含有 GluN2B 的 NMDA 受体与 18 种拮抗剂的相互作用。首先,使用 Catalyst(HipHop 模块)为分为两组的拮抗剂生成了两个不同的药效团模型。“ifenprodil 组”拮抗剂的药效团包括三个疏水区、一个氢键供体和一个氢键受体,“EVT101 组”拮抗剂的药效团涉及一个芳环、两个疏水区和一个氢键受体。对接结果和药效团模型对抗允许对药效特征进行加权和整合结构信息。这导致提出了两种作用模型,用于 GluN2B 结合腔内的两组拮抗剂。“ifenprodil 组”拮抗剂的相互作用模型由一个疏水区、一个氢键供体、一个氢键受体和一个芳环组成,而另一方面,“EVT101 组”拮抗剂的相互作用模型包括三个疏水区和一个芳环。